Annex G of CVM Resolution No. 80/2022, as amended

<table>
<tr>
<td>1. Provide a detailed justification of the purpose and the expected economic effects of the transaction,</td>
<td>
With the purpose of providing additional support for the execution of Vale S.A.’s (“Vale” or the “Company”) ongoing Share Buyback Program, approved by the Company’s Board of Directors (“BoD”) on February 19, 2025, and effective until August 18, 2026 (the “Buyback Program”), the BoD has authorized the use of one or more of the financial instruments listed in items (i) to (iii) below (collectively, the “Financial Instruments”), with top-tier financial institutions, in compliance with applicable legislation and the following conditions:
(i) Total Return Equity Swap (“Equity Swap”) – a contract in which the Company receives the total return of Vale shares traded on B3 S.A. – Brasil, Bolsa, Balcão (“B3”), including price variation and dividends, from a counterparty (bank), in exchange for payments based on a fixed or floating rate (e.g., CDI/SOFR + spread). This allows artificial exposure to the asset without physical ownership, no immediate cash outflow, and settlement exclusively in cash;
(ii) Enhanced Share Repurchase (“ESR”) – a contract in which the Company engages a bank to execute the full or partial repurchase of shares and/or American Depositary Receipts (“ADRs”) in an optimized manner, ensuring a discount relative to the average market price. The receipt and payment of shares and/or ADRs by Vale occur throughout the execution period;
(iii) Accelerated Share Repurchase (“ASR”) – a contract in which the Company makes an upfront payment to a bank to repurchase a predetermined number of its shares and/or ADRs. The bank immediately delivers the shares and/or ADRs to the Company by borrowing them from the market, with the final repurchase price adjusted based on the volume-weighted average price (VWAP) over a period, potentially including price adjustments via payment, derivative (swap), or additional share delivery.
The use of one or more of these Financial Instruments will provide additional support to the execution strategy of Vale’s ongoing Share Buyback Program, considering the rationale of (i) the attractiveness of its expected return compared to alternative capital allocation options, (ii) the expectation of share appreciation based on different valuation methodologies, and (iii) the signaling of continued capital allocation discipline and confidence in the Company.
The expected economic effect of the ESR and ASR operations is to accelerate the execution of the Share Buyback Program, increasing the number of treasury shares and correspondingly reducing the number of outstanding shares issued by Vale. Subsequently, upon resolution to cancel the treasury shares, there will be an increase in the shareholders’ ownership percentage, which will lead to the
</td>
</tr>
</table>

	appropriate amendment of the caput of Article 5 of the Company's Bylaws. The use of Equity Swaps allows Vale to increase its economic exposure to its own shares without the need to acquire them, providing greater financial flexibility and reducing the immediate impact on cash flow.
2. Provide the number of shares (i) outstanding and (ii) currently held in Treasury,	As of June 30, 2025, the Company held: (i) 4,268,778,775 outstanding shares, and (ii) 270,228,793 treasury shares.
3. Provide the number of shares that may be acquired or disposed of,	The Financial Instruments described above may be executed up to a maximum volume of shares issued by the Company which, when added to the shares repurchased directly under the currently effective Share Buyback Program, shall not exceed 120,000,000 common shares issued by Vale or depositary receipts representing such shares.
4. Describe the main characteristics of the derivative instruments the company may use, if any,	Equity Swap contracts involve the exchange of future financial flows based on Vale shares traded on B3, whereby the Company receives the price variation of the exchange-traded shares plus dividends paid during the period, and pays the variation of a reference interest rate, such as CDI or SOFR, plus an annual spread for the period of each respective contract. Settlement is exclusively financial. The ASR involves engaging a financial institution to execute the full or partial repurchase of Vale's shares and/or ADRs, ensuring a discount relative to the average market price during the agreed period for the bank to carry out the repurchase. Vale receives and pays for all or part of the shares immediately, with a price adjustment based on the average price executed by the bank. The price adjustment mechanism may require a swap contract between Vale and the financial institution for the notional value of the transaction, whereby the Company pays the price variation of Vale shares traded on the exchange plus dividends paid during the period, and receives the variation of a reference interest rate, such as CDI or SOFR, with or without an annual spread, for the term of each respective contract. Settlement is exclusively financial. As for the ESR instrument, it is not considered a derivative, as it is a strategy that supports the physical repurchase of Vale shares.
5. Describe any existing agreements or voting guidelines between the company and the counterparty to the transactions, if any,	Not applicable, as the Equity Swap will establish a settlement method that is exclusively financial and will not include any provisions regarding the exercise of voting rights related to the Company's shares that may eventually be held by the counterparty (financial institution). As for the other Financial Instruments (ESR and ASR), ownership of the shares will be transferred to Vale at the time of contracting or repurchase by the financial institution.
6. In the event of transactions carried out outside organized securities markets, provide the following information:	The Financial Instruments to be contracted must include a clause ensuring that payments made or received by the Company will be calculated based on the variation in the

a. he maximum (minimum) price at which the shares will be acquired (disposed of); and, b. if applicable, the reasons justifying the execution of the transaction at prices more than 10% (ten percent) above, in the case of acquisition, or more than 10% (ten percent) below, in the case of disposal, the volume-weighted average price over the previous 10 (ten) trading sessions,	share price over specific periods. The reference price of the shares at the beginning of each of these periods must not be more than 10% above or below the volume-weighted average price over the 10 previous trading sessions, in compliance with CVM Resolution No. 77/2022. It is also worth noting that the Equity Swap contracts will be registered by B3.
7. f applicable, provide the impacts that the transaction will have on the shareholding control structure or the management structure of the company.	No significant impact is expected on the shareholding control structure or the management structure of the company,
8. Identify the counterparties, if known, and, in the case of a related party to the company, as defined by the applicable accounting rules, also provide the information required under Article 9 of CVM Resolution No. 81, dated March 29, 2022,	The counterparties to the Financial Instruments will be selected by the Treasury and Corporate Finance Department from among top-tier financial institutions, which must not be related parties to the Company.
9. Indicate the intended use of the proceeds, if applicable;	Due to the nature of Equity Swap contracts, it is not possible to determine in advance whether the Company will generate proceeds from them. If such proceeds are realized, the Company will use the funds to strengthen its cash position and continue executing its business plan and strategy. In the case of ESR and ASR, no proceeds are expected.
10. Indicate the maximum term for the settlement of the authorized transactions,	The Financial Instruments must be settled by the Company no later than August 18, 2026, which is the expiration date of the currently effective Share Buyback Program.
11. Identify the institutions that will act as intermediaries, if any,	Not applicable.
12. Specify the available funds to be used, in accordance with Article 8, Paragraph 1, of CVM Resolution No. 77, dated March 29, 2022,	Funds available in profit or capital reserves, as recorded in the Company's Financial Statements for the fiscal year ended December 31, 2025, will be used, in accordance with Article 8, Paragraph 1, of CVM Resolution No. 77/2022.
13. Specify the reasons why the members of the board of directors feel confident that the share buyback will not impair the fulfillment of obligations to creditors nor the payment of mandatory, fixed, or minimum dividends.	The members of the BoD consider that the Company's current financial position is compatible with the execution of the Financial Instruments under the conditions hereby approved, and that such contracts will not compromise the fulfillment of obligations assumed with creditors, nor will they affect the payment of mandatory, fixed, or minimum dividends. Accordingly, the Board believes that allocating the Company's cash resources to these Financial Instruments is appropriate, with the objective of capturing the potential appreciation of the shares, based on the perception that they are currently undervalued in the market.